弥漫大B细胞淋巴瘤中SLC38A5的表达及其与临床病理特征、预后的关系OA

Objective To investigate the expression pattern of SLC38A5 in diffuse large B-cell lymphoma(DLBCL)and analyze its relationship with clinicopathological features and prognosis.Methods Clinical data from 150 cases of DLBCL patients were collected.Immunohistochemistry was used to detect the expression of the SLC38A5 protein.The correlations between SLC38A5 expression and clinical pathological characteristics,immunophenotypes,and prognosis of patients were analyzed.Cell viability testing and colony formation experiments were conducted to ana-lyze the effects of SLC38A5 overexpression and knockdown on the growth of DLBCL cells.Co-expression analysis of SLC38A5 and metabolism-related genes was performed using GEO public database,and preliminarily explore its po-tential mechanisms related to metabolism.Results SLC38A5 positive expression was detected in 28 cases,with a positive rate of 18.7%.Regarding clinical parameters,SLC38A5 positivity was associated with a higher Ann Arbor stage(P=0.002).In terms of pathological parameters,SLC38A5 positivity was correlated with the(non-GCB)sub-type(P=0.027),MUM-1 positivity(P=0.012),CD10 negativity(P=0.031),and MYC positivity(P<0.001).Kaplan-Meier survival analysis showed that patients with SLC38A5 positivity had significantly shorter overall survival(OS)(P=0.039)and progression-free survival(PFS)(P=0.034)compared to those with SLC38A5 negative pa-tients.Cox regression analysis results indicated that SLC38A5 positivity was associated with poor OS in patients(P=0.046).Functional studies demonstrated the overexpression of SLC38A5 significantly enhanced,while knockdown of SLC38A5 inhibited,the cell viability and colony-forming ability of DLBCL cells(P<0.000 1).The expression of SLC38A5 was positively correlated with SLC1A5 expression(r=0.663 0,P<0.000 1),negatively correlated with GLUD1 expression(r=-0.173 7,P=0.000 4),and positively correlated with GLS expression(r=0.337 8,P<0.000 1).Conclusion The expression of SLC38A5 in DLBCL is associated with adverse clinicopathological fea-tures,including advanced clinical stage,non-GCB subtype,and MYC positivity,and indicates poor survival progno-sis.SLC38A5 promotes DLBCL cell proliferation and colony formation.The expression of SLC38A5 may be closely as-sociated with the uptake and initial catabolic processes of glutamine.